administered

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

Source Node:
Time Stamp: March 14, 2025 2:33 PM - Modified On: March 14, 2025 - Published By:
Source Cluster:
Republished By Plato

Interim Analysis Expected End of 2Q 2025 BETHESDA, Md., March 13, 2025 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson’s disease (PD) in its Phase 1b clinical trial of GT-02287, the Company’s lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation. “Initiation of dosing in our Phase 1b clinical trial represents an

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Call of Duty 2022 Title Has Apparently Been Leaked

Source Node: https://www.dbltap.com/posts/call-of-duty-2022-title-has-apparently-been-leaked-01fhjvjth2ap?utm_source=RSS
Time Stamp: October 9, 2021 1:31 PM - Modified On: October 9, 2021 - Published By:
Source Cluster:
Republished By Plato

Call of DutyPhoto courtesy of ActivisionThe Call of Duty franchise is notoriously bad at containing leaks. Call of Duty 2022 will apparently be called Call of Duty: Modern Warfare II.Tom Henderson, a writer at IGN, confirmed the title of next year's installment on Saturday, Oct. 9. Henderson also added that the game's artwork is reportedly very well done. His confirmation corroborates a leak last month suggesting that CoD 2022 will be a sequel to 2019's Modern Warfare. No other information came from the previous leak, as much is likely still